Orphan Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025
- September 2020 •
- 106 pages •
- Report ID: 5968605 •
- Format: PDF
Orphan drugs refer to pharmaceutical products used for the diagnosis, prevention and treatment of rare medical disorders. These drugs are manufactured to meet a specific public health requirement and usually have a limited market as they are produced for a small group of patients. They are effective against numerous oncological, metabolic, hematologic, immunologic, infectious and neurological diseases. Medical ailments, such as lymphoma, leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, multiple myeloma and renal cell carcinoma, are often life-threatening, chronic, progressive, degenerative and disabling and require specific treatment alternatives that are effective for their particular symptoms.
The increasing prevalence of cancer and other rare genetic disorders is one of the key factors driving the growth of the market. Pharmaceutical manufacturers are developing innovative orphan drugs to provide personalized therapy to patients. The market is also being driven by increasing awareness among the masses regarding the benefits of orphan drugs. The emergence of new pharmaceutical drug manufacturers and the implementation of favorable government policies to inhibit the spread of contagious diseases are also contributing to the market growth. Additionally, various product innovations, such as the development of biological orphan drugs, are acting as other growth-inducing factors. These drugs can treat diseases, such as cancer, and reverse the damage caused to the stem cells, which is facilitating their overall demand significantly. Other factors, including improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities, are expected to drive the market further. Looking forward, the analyst expects the global orphan drugs market to exhibit moderate growth during the next five years.
Breakup by Drug Type:
Breakup by Disease Type:
Breakup by Phase:
Breakup by Top Selling Drugs:
Breakup by Distribution Channel:
Breakup by Region:
Middle East and Africa
The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Alexion Pharmaceuticals Inc., Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), Jazz Pharmaceuticals Plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.
Key Questions Answered in This Report:
How has the global orphan drugs market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global orphan drugs market?
What are the key regional markets?
What is the breakup of the market based on the drug type?
What is the breakup of the market based on the disease type?
What is the breakup of the market based on the phase?
What is the breakup of the market based on the top selling drugs?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global orphan drugs market and who are the key players?
What is the degree of competition in the industry?